Skip to main content
MedPathMedPath Home
Clinical Trials/NCT01841814
NCT01841814
Withdrawn
Phase 4

Evolution of Bone Mineral Density (BMD) in Patients With Lymphoma Undergoing Chemotherapy: Prospective Longitudinal Study Over 12 Months.

Centre Hospitalier Universitaire, Amiens1 site in 1 countryApril 2013
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsLymphomaOsteoporosis

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Lymphoma
Sponsor
Centre Hospitalier Universitaire, Amiens
Locations
1
Primary Endpoint
Measurement of bone mineral density (BMD).
Status
Withdrawn
Last Updated
9 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSitesSimilar Trials

Overview

Brief Summary

The purpose of this study is to assess changes of bone mineral density (BMD) at 12 months during the therapeutic management of patients with lymphoma.

Registry
clinicaltrials.gov
Start Date
April 2013
End Date
April 2013
Last Updated
9 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • •Subjects aged 18 to 80 with lymphoma,
  • •Histological diagnosis of Hodgkin's lymphoma (HL) or non-Hodgkin lymphoma (NHL) of follicular or aggressive (large cell or other),
  • •Patients who have not yet started their chemotherapy or who have started for less than a month
  • •Patient has signed informed consent.

Exclusion Criteria

  • •Pathological fractures at the time of initial diagnosis of lymphoma,
  • •Compression of neurological epidural,
  • •Patients receiving treatment for osteoporosis (including bisphosphonates, selective modulators of estrogen receptor, calcitonin and parathyroid hormone Teriparatide).
  • •Discovery of osteoporosis or osteopenia fracture during the initial evaluation requiring the establishment of an osteoporosis treatment,
  • •Radiotherapy to the lumbar spine or hip studied,
  • •Location of bone lymphoma in the lumbar spine or hip studied,
  • •History of disorders affecting bone metabolism (prostate cancer with androgen, stomach cancer, hyperparathyroidism, hyperthyroidism, uncontrolled ...)
  • •A person incapable of giving consent personally,
  • •Pregnant or breastfeeding women,
  • •Protected Person (under guardianship)

Outcomes

Primary Outcomes

Measurement of bone mineral density (BMD).

Time Frame: Change from Baseline of bone mineral density at 12 months.

Patients will have a review of bone densitometry.

Study Sites (1)

Loading locations...

Similar Trials

Terminated
Phase 2
Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaOsteogenesis Imperfecta
NCT05312697Ultragenyx Pharmaceutical Inc2
Completed
Not Applicable
6 Years Study on Changes in Bone Quality, Bone Turnover and Curve Severity in AIS With and Without Calcium and Vit-D SupplementationScoliosisVitamin DBone
NCT02904421Chinese University of Hong Kong330
Completed
Not Applicable
Bone Mineral Density in Women With Uterine Fibroids or EndometriosisUterine FibroidEndometriosis
NCT03744507Myovant Sciences GmbH660
Completed
Not Applicable
A Comparison of Changes in Bone Density With the Same Bone-health Plan, But With Different Bone-health SupplementsOsteopenia
NCT01114685Integrative Health Technologies, Inc.354
Unknown
Not Applicable
Periprosthetic Bone Mineral Density Changes After Implantation Of A Short Hip Stem Compared To A Straight StemOsteoarthritis, Hip
NCT03147131University Hospital Ulm126